Abstract
The influence of interferon (IFN)-β on cytokine release by immune cells remains controversial. This study compared IFN-β1b effects on mononuclear cells, CD4+ and CD8+ T cells derived from healthy controls and relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) patients. Effects of IFN-β1b (0-10,000 U/ml) on cytokine release were determined in cell culture. IFN-β1b inhibited IFN-γ and induced interleukin (IL)-4 selectively in RRMS-derived CD4+ T cells. IL-10 was significantly induced in all cell populations from RRMS but only marginally in PPMS. IL-5 was always inhibited; IL-17A remained unaltered. These in vitro data parallel clinical observations that IFN-β is most effective in RRMS.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
CD4-Positive T-Lymphocytes / drug effects*
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / drug effects*
-
CD8-Positive T-Lymphocytes / immunology
-
Cell Proliferation / drug effects
-
Cells, Cultured
-
Cytokines / metabolism*
-
Dose-Response Relationship, Drug
-
Humans
-
Immunologic Factors / pharmacology*
-
Interferon beta-1b
-
Interferon-beta / pharmacology*
-
Middle Aged
-
Multiple Sclerosis, Chronic Progressive / diagnosis
-
Multiple Sclerosis, Chronic Progressive / immunology*
-
Multiple Sclerosis, Relapsing-Remitting / diagnosis
-
Multiple Sclerosis, Relapsing-Remitting / immunology*
-
Severity of Illness Index
-
Young Adult
Substances
-
Cytokines
-
Immunologic Factors
-
Interferon beta-1b
-
Interferon-beta